Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02557490|
Recruitment Status : Unknown
Verified July 2015 by Zhu Xu, Beijing Cancer Hospital.
Recruitment status was: Recruiting
First Posted : September 23, 2015
Last Update Posted : September 23, 2015
|Condition or disease||Intervention/treatment||Phase|
|Colon Cancer Liver Metastasis||Drug: oxaliplatin and raltitrexed||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases|
|Study Start Date :||January 2015|
|Estimated Primary Completion Date :||December 2016|
|Estimated Study Completion Date :||December 2017|
Experimental: Oxaliplatin by TACE
Oxaliplatin for the therapy of Colorectal Cancer With Liver Metastases by TACE.No interventions was raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
Drug: oxaliplatin and raltitrexed
TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.
Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)
No Intervention: Raltitrexed by TACE
Raltitrexed for the therapy of Colorectal Cancer With Liver Metastases by TACE.
- Progression-free survival (PFS) [ Time Frame: three years ]
- overall survival (OS) [ Time Frame: three years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02557490
|Beijing Cancer Hospital||Recruiting|
|Beijing, Beijing, China, 100142|
|Contact: Zhu Xu, Master 0086-10-88195476 firstname.lastname@example.org|
|Principal Investigator: Zhu Xu, Master|